These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1817 related articles for article (PubMed ID: 29532693)

  • 1. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
    Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
    PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging therapies in psoriasis.
    Leonardi CL; Gordon KB
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
    Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics for Psoriasis.
    Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
    Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.